fexofenadine has been researched along with Rhinitis, Allergic, Nonseasonal in 34 studies
fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl
fexofenadine : A piperidine-based anti-histamine compound.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nonsedating antihistamines (nsAHs) are recommended as first-line therapeutics for the treatment of mast cell-driven disorders, including allergic rhinitis and urticaria." | 5.14 | Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines. ( dos Santos, RV; Lima, HC; Magerl, M; Mlynek, A, 2009) |
| "An assessment of the severity of allergic rhinitis symptoms was performed for all patients (n = 260) pre- and 7 days into fexofenadine." | 3.79 | The role of multidrug resistance-1 (MDR1) variants in response to fexofenadine among Jordanians. ( Al-Azzam, SI; Alzoubi, KH; Khabour, OF; Mayyas, F, 2013) |
| " However, the effect of long-term use of montelukast, a cystenil leukotriene receptor antagonist, on skin prick test hasn't been full elucidated." | 2.78 | The effect of montelukast on wheal reactions in skin prick tests: a double-blind-placebo-controlled randomized trial. ( Aydogan, M; Aydogmus, CY; Bulan, K; Siraneci, R, 2013) |
| " Before the amendment, assessments included physical examination, vital signs reporting (oral temperature, heart rate, and respiratory rate), and adverse event (AE) reporting." | 2.73 | Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old. ( Hampel, FC; Kittner, B; Lanier, R; Milgrom, H, 2007) |
| "In the combined population, the incidence of treatment-emergent adverse events (TEAEs) was comparable between groups (placebo, 48." | 2.73 | Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis. ( Hampel, FC; Kittner, B; van Bavel, JH, 2007) |
| "Pretreatment with fexofenadine 2 hours before immunotherapy significantly reduced the occurrence of severe SRs (P = ." | 2.72 | Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis. ( Murata, K; Nakai, Y; Ohashi, Y, 2006) |
| " In Treatment A, healthy subjects received a single, oral dose of FEX 180 mg/PSE 240 mg combination tablet on Day 1 followed by 6 days of once-daily dosing beginning on Day 4." | 2.71 | Single-dose and steady-state bioequivalence of fexofenadine and pseudoephedrine combination tablets compared with individual formulations in healthy adults. ( Agrawala, P; Haribhakti, R; Howard, DR; Kittner, B, 2005) |
| " and adverse events were recorded in diary cards by the patients in form of scores as well as by the investigator at each visit." | 2.71 | The efficacy and safety of 30 mg fexofenadine HCl bid in pediatric patients with allergic rhinitis. ( Direkwattanachai, C; Ngamphaiboon, J; Tiensuwan, M; Vangveeravong, M; Visitsunthorn, N, 2005) |
| "Subjects evaluated at a referral medical center were placed on traditional dosing of fexofenadine at 60 mg, twice daily, or placebo in a double-blind, crossover fashion for 1 week before the nasal challenge." | 2.70 | Evaluation of cytokines in nasal secretions after nasal antigen challenge: lack of influence of antihistamines. ( Bensch, GW; Borish, LC; Nelson, HS, 2002) |
| " Adverse events and onset of symptom relief were also recorded by every patient." | 2.69 | A non-comparative trial of the efficacy and safety of fexofenadine for treatment of perennial allergic rhinitis. ( Bunnag, C; Chochaipanichnon, L; Jareoncharsri, P; Kongpatanakul, S; Limprasertsiri, S; Pumhirun, P; Supiyaphun, P; Tunsuriyawong, P, 2000) |
| " No major cytochrome P450 inhibition has been reported with desloratadine, fexofenadine and levocetirizine, and the bioavailability of desloratadine is minimally affected by drugs interfering with transporter molecules." | 2.44 | Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. ( Devillier, P; Faisy, C; Roche, N, 2008) |
| " Second-generation antihistamines have become increasingly popular because of their comparable efficacy and lower incidence of adverse effects relative to their first-generation counterparts, and the safety and efficacy of this drug class are established in the adult population." | 1.35 | Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. ( Moeller, ML; Nahata, MC; Phan, H, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.88) | 18.2507 |
| 2000's | 28 (82.35) | 29.6817 |
| 2010's | 4 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guzman, Y | 1 |
| Bulan, K | 1 |
| Aydogan, M | 1 |
| Siraneci, R | 1 |
| Aydogmus, CY | 1 |
| Alzoubi, KH | 1 |
| Khabour, OF | 1 |
| Al-Azzam, SI | 1 |
| Mayyas, F | 1 |
| Izumi, N | 1 |
| Mizuguchi, H | 1 |
| Umehara, H | 1 |
| Ogino, S | 1 |
| Fukui, H | 1 |
| Akiyama, K | 1 |
| Karaki, M | 1 |
| Kobayshi, R | 1 |
| Dobashi, H | 1 |
| Ishida, T | 1 |
| Mori, N | 1 |
| dos Santos, RV | 1 |
| Magerl, M | 1 |
| Mlynek, A | 1 |
| Lima, HC | 1 |
| Li, AM | 1 |
| Abdullah, VJ | 1 |
| Tsen, CS | 1 |
| Au, CT | 1 |
| Lam, HS | 1 |
| So, HK | 1 |
| Chan, MH | 1 |
| Leung, AW | 1 |
| Chan, IH | 1 |
| Lam, CW | 1 |
| Ng, PC | 1 |
| Phan, H | 1 |
| Moeller, ML | 1 |
| Nahata, MC | 1 |
| Shaikh, WA | 1 |
| Shaikh, SW | 1 |
| Cingi, C | 1 |
| Gunhan, K | 1 |
| Gage-White, L | 1 |
| Unlu, H | 1 |
| Lanier, BQ | 1 |
| Abelson, MB | 2 |
| Berger, WE | 1 |
| Granet, DB | 1 |
| D'Arienzo, PA | 1 |
| Spangler, DL | 2 |
| Kägi, MK | 1 |
| Simons, FE | 1 |
| J Semus, M | 1 |
| Goritz, SS | 1 |
| Simons, KJ | 1 |
| Chervinsky, P | 1 |
| Casale, T | 1 |
| Townley, R | 1 |
| Tripathy, I | 1 |
| Hedgecock, S | 1 |
| Fowler-Taylor, A | 1 |
| Shen, H | 1 |
| Fox, H | 1 |
| Ober, A | 1 |
| Gotnes, PJ | 1 |
| Gelfand, EW | 1 |
| Cui, ZH | 1 |
| Takeda, K | 1 |
| Kanehiro, A | 1 |
| Joetham, A | 1 |
| Lee, DK | 3 |
| Gray, RD | 1 |
| Robb, FM | 1 |
| Fujihara, S | 2 |
| Lipworth, BJ | 3 |
| Gardiner, M | 1 |
| Haggart, K | 1 |
| Jackson, CM | 1 |
| Soutar, PC | 1 |
| Fardon, TC | 1 |
| Howard, DR | 1 |
| Haribhakti, R | 1 |
| Kittner, B | 3 |
| Agrawala, P | 1 |
| Berkowitz, RB | 1 |
| Braker, S | 1 |
| Lutz, C | 1 |
| Jones, P | 1 |
| Meeves, S | 1 |
| Qiu, C | 1 |
| Varghese, ST | 1 |
| Georges, G | 1 |
| Ngamphaiboon, J | 1 |
| Direkwattanachai, C | 1 |
| Visitsunthorn, N | 1 |
| Vangveeravong, M | 1 |
| Tiensuwan, M | 1 |
| Ohashi, Y | 1 |
| Nakai, Y | 1 |
| Murata, K | 1 |
| Magen, E | 1 |
| Yosefy, C | 1 |
| Viskoper, RJ | 1 |
| Mishal, J | 1 |
| Lehman, JM | 1 |
| Blaiss, MS | 1 |
| Milgrom, H | 1 |
| Lanier, R | 1 |
| Hampel, FC | 2 |
| van Bavel, JH | 1 |
| Devillier, P | 1 |
| Roche, N | 1 |
| Faisy, C | 1 |
| Ricard, N | 1 |
| Kind, P | 1 |
| Christian, S | 1 |
| Jensen, M | 1 |
| Stewart, J | 1 |
| Bunnag, C | 1 |
| Jareoncharsri, P | 1 |
| Tunsuriyawong, P | 1 |
| Pumhirun, P | 1 |
| Limprasertsiri, S | 1 |
| Chochaipanichnon, L | 1 |
| Supiyaphun, P | 1 |
| Kongpatanakul, S | 1 |
| Lee, J | 1 |
| Cummins, G | 2 |
| Okamoto, L | 1 |
| Liao, E | 1 |
| Leahy, M | 1 |
| Ciprandi, G | 1 |
| Cosentino, C | 1 |
| Milanese, M | 1 |
| Mondino, C | 1 |
| Canonica, GW | 1 |
| Bensch, GW | 1 |
| Nelson, HS | 1 |
| Borish, LC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age[NCT04957927] | Phase 4 | 60 participants (Anticipated) | Interventional | 2020-12-12 | Recruiting | ||
| The Effects of Omalizumab on the Late-phase Response to Nasal Allergen Challenge[NCT01003301] | Phase 2 | 19 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Pilot Study of the Effect of Omalizumab on Basophil and Mast Responses to Intranasal Cat Allergen Challenge[NCT00604786] | 18 participants (Actual) | Interventional | 2007-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reduction in skin late phase size at 8 hours at the time of blood basophil hypo-responsiveness to allergen will be reduced compared to baseline. (NCT01003301)
Timeframe: Baseline, 2-6 wks
| Intervention | percentage decline from NAC-1 (Mean) |
|---|---|
| Omalizumab | 54 |
| Placebo | 0 |
"Flow cytometry in mean fluorescence units.~100%*[(3.5 month value minus baseline value)/baseline value]" (NCT00604786)
Timeframe: Change from baseline to 3.5 months
| Intervention | percentage of basophil surface IgE (Mean) |
|---|---|
| Omalizumab Subcutaneous | -95 |
| Placebo Subcutaneous | -10 |
2 reviews available for fexofenadine and Rhinitis, Allergic, Nonseasonal
| Article | Year |
|---|---|
Selecting the optimal oral antihistamine for patients with allergic rhinitis.
Topics: Administration, Oral; Cardiovascular System; Central Nervous System; Cetirizine; Drug Interactions; | 2006 |
Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.
Topics: Cetirizine; Drug Interactions; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Rhinitis, | 2008 |
22 trials available for fexofenadine and Rhinitis, Allergic, Nonseasonal
| Article | Year |
|---|---|
The effect of montelukast on wheal reactions in skin prick tests: a double-blind-placebo-controlled randomized trial.
Topics: Acetates; Allergens; Animals; Asthma; Chi-Square Distribution; Child; Cyclopropanes; Dose-Response R | 2013 |
Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines.
Topics: Adult; Allergens; Animals; Dermatophagoides pteronyssinus; Dibenzazepines; Double-Blind Method; Fema | 2009 |
Leukotriene receptor antagonist in the treatment of childhood allergic rhinitis--a randomized placebo-controlled study.
Topics: Acetates; Adolescent; Asthma; Child; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; | 2009 |
Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis.
Topics: Acetates; Adult; Airway Resistance; Anti-Allergic Agents; Case-Control Studies; Cyclopropanes; Drug | 2010 |
Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.
Topics: Administration, Intranasal; Administration, Topical; Adult; Allergens; Androstadienes; Anti-Allergic | 2002 |
H1-antihistaminic activity of cetirizine and fexofenadine in allergic children.
Topics: Anti-Allergic Agents; Cetirizine; Child; Cross-Over Studies; Double-Blind Method; Female; Histamine | 2003 |
Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; | 2003 |
Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; | 2003 |
Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; | 2003 |
Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; | 2003 |
Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
Topics: Administration, Intranasal; Administration, Oral; Administration, Topical; Adult; Aged; Allergens; A | 2003 |
A placebo-controlled evaluation of butterbur and fexofenadine on objective and subjective outcomes in perennial allergic rhinitis.
Topics: Adult; Anti-Allergic Agents; Cross-Over Studies; Double-Blind Method; Female; Histamine H1 Antagonis | 2004 |
Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Anti-Allergic Agents; Cetirizine; Cross-Ove | 2004 |
Effects of single or combined histamine H1-receptor and leukotriene CysLT1-receptor antagonism on nasal adenosine monophosphate challenge in persistent allergic rhinitis.
Topics: Acetates; Adult; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Drug Combinations; Female; | 2004 |
Single-dose and steady-state bioequivalence of fexofenadine and pseudoephedrine combination tablets compared with individual formulations in healthy adults.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Cross-Over Studies; Delayed-Action Preparations; Drug | 2005 |
Efficacy of fexofenadine in the prophylactic control of cat allergen-induced allergic rhinitis.
Topics: Adolescent; Animals; Anti-Allergic Agents; Cats; Child; Cross-Over Studies; Double-Blind Method; Env | 2006 |
The efficacy and safety of 30 mg fexofenadine HCl bid in pediatric patients with allergic rhinitis.
Topics: Anti-Allergic Agents; Asian People; Child; Female; Histamine H1 Antagonists; Humans; Male; Multicent | 2005 |
Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis.
Topics: Adult; Anti-Allergic Agents; Cedrus; Dermatophagoides farinae; Desensitization, Immunologic; Female; | 2006 |
Treatment of allergic rhinitis can improve blood pressure control.
Topics: Adult; Analysis of Variance; Androstadienes; Anti-Allergic Agents; Antihypertensive Agents; Biomarke | 2006 |
Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old.
Topics: Age Factors; Anti-Allergic Agents; Body Temperature; Child, Preschool; Cough; Double-Blind Method; E | 2007 |
Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis.
Topics: Administration, Oral; Blood Pressure; Body Temperature; Body Weight; Child, Preschool; Electrocardio | 2007 |
Link between patient preferences and treatment outcomes in seasonal allergic rhinitis: an empiric investigation.
Topics: Adult; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Loratadine; Male; Patient Sati | 1999 |
A non-comparative trial of the efficacy and safety of fexofenadine for treatment of perennial allergic rhinitis.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Drug Administration Schedule; Electrocardiography; Fe | 2000 |
Fexofenadine reduces nasal congestion in perennial allergic rhinitis.
Topics: Adolescent; Adult; Animals; Dose-Response Relationship, Drug; Double-Blind Method; Female; Histamine | 2001 |
Evaluation of cytokines in nasal secretions after nasal antigen challenge: lack of influence of antihistamines.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Chemokine CCL3; Chemokine CCL4; Cross-Over Studies; C | 2002 |
10 other studies available for fexofenadine and Rhinitis, Allergic, Nonseasonal
| Article | Year |
|---|---|
You're the flight surgeon: nasal congestion and Eustachian tube dysfunction.
Topics: Adult; Aerospace Medicine; Desensitization, Immunologic; Eustachian Tube; Histamine H1 Antagonists, | 2013 |
The role of multidrug resistance-1 (MDR1) variants in response to fexofenadine among Jordanians.
Topics: Adult; Anti-Allergic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Tra | 2013 |
Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asthma; Butyrophenones; Cetirizine; Child; Chlorpheniram | 2008 |
IL-16 variability and modulation by antiallergic drugs in a murine experimental allergic rhinitis model.
Topics: Animals; Anti-Allergic Agents; Carbazoles; Disease Models, Animal; Eosinophils; Female; Immunoglobul | 2009 |
Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast.
Topics: Acetates; Administration, Oral; Adult; Anti-Allergic Agents; Anti-Asthmatic Agents; Astemizole; Ceti | 2009 |
Allergies in India: a study on medication compliance.
Topics: Adolescent; Adult; Anti-Allergic Agents; Asthma; Bronchodilator Agents; Budesonide; Child; Ethanolam | 2009 |
Effects of fexofenadine on T-cell function in a murine model of allergen-induced airway inflammation and hyperresponsiveness.
Topics: Administration, Inhalation; Adoptive Transfer; Allergens; Animals; Anti-Allergic Agents; Antibody Sp | 2003 |
Seldane approval may be withdrawn by FDA.
Topics: Drug Approval; Drug Interactions; Histamine H1 Antagonists; Humans; Rhinitis, Allergic, Perennial; T | 1997 |
A descriptive analysis of the use and cost of new-generation antihistamines in the treatment of allergic rhinitis: a retrospective database analysis.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Cetirizine; Child; Databases as Topic; Drug Utilizati | 2001 |
The costs of nonsedating antihistamine therapy for allergic rhinitis in managed care: an updated analysis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Cetirizine; Child; Cohort Studies; Drug Costs; Eco | 2001 |